Hereditary angioedema: Management of laryngeal attacks

American Journal of Rhinology and Allergy

Volumn 25, Issue 6, 2011, Pages 379-382

  Christiansen, Sandra C ^a   Zuraw, Bruce L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; BRADYKININ ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; KALLIKREIN INHIBITOR;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG HALF LIFE; HUMAN; INJECTION SITE PAIN; LARYNX DISORDER; PROPHYLAXIS; TREATMENT RESPONSE;

ANGIOEDEMAS, HEREDITARY; BRADYKININ; COMPLEMENT C1 INACTIVATOR PROTEINS; DISEASE MANAGEMENT; HUMANS; LARYNGEAL EDEMA; PEPTIDES; UNITED STATES;

EID: 84455189511     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2011.25.3670     Document Type: Conference Paper

References (49)

1. Zilberberg M, Jacobsen T, and Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007. Allergy Asthma Proc 31:511-519, 2010.
2. Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 31:407-414, 2010.
3. Bork K, Meng G, Staubach P, and Hardt J. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am J Med 119:267-274, 2006. (Pubitemid 43255068)
4. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 359:1027-1036, 2008.
5. Bork K, Hardt J, Schicketanz KH, and Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163:1229-1235, 2003. (Pubitemid 36613077)
6. Bork K, and Ressel N. Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apheresis Sci 29:235-238, 2003. (Pubitemid 37315588)
7. Bork K, and Barnstedt SE. Laryngeal edema and death from asphyxiation after tooth extraction in four patients with hereditary angioedema. J Am Dent Assoc 134:1088-1094, 2003. (Pubitemid 38175476)
8. Papadopoulou-Alataki E. Upper airway considerations in hereditary angioedema. Curr Opin Allergy Clin Immunol 10:20-25, 2010.
9. Pickering RJ, Good RA, Kelly JR, and Gewurz H. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1:326-330, 1969.
10. Agostoni A, Bergamaschini L, Martignoni G, et al. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy 44:299-301, 1980. (Pubitemid 10110161)
11. Gadek JE, Hosea SW, Gelfand JA, et al. Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 302:542-546, 1980. (Pubitemid 10184278)
12. Marasini B, Cicardi M, Martignoni GC, and Agostoni A. Treatment of hereditary angioedema. Klin Wochenschr 56:819-823, 1978. (Pubitemid 8395771)
13. Bergamaschini L, Cicardi M, Tucci A, et al. C1 INH concentrate in the therapy of hereditary angioedema. Allergy 38:81-84, 1983. (Pubitemid 13142101)
14. Bork K, and Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 161:714-718, 2001. (Pubitemid 32200225)
15. Kirschfink M, and Mollnes TE. C1-inhibitor: An anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother 2:1073-1083, 2001. (Pubitemid 32633709)
16. Logan RA, and Greaves MW. Hereditary angio-oedema: Treatment with C1 esterase inhibitor concentrate. J R Soc Med 77:1046-1048, 1984. (Pubitemid 15177079)
17. Agostoni A, and Cicardi M. Hereditary and acquired C1-inhibitor deficiency: Biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71:206-215, 1992.
18. Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 38:540-549, 1998. (Pubitemid 28317229)
19. Bork K, Meng G, Staubach P, and Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45:1774-1784, 2005. (Pubitemid 43923905)
20. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124:801-808, 2009.
21. Bernstein J, Ritchie B, Levy R, et al. Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity. Allergy Asthma Proc 32:36-42, 2010.
22. Craig TJ, Wasserman RL, Levy RJ, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 30:823-829, 2010. (PMCID: 2970824.)
23. Bork K, and Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 83:677-682, 1989. (Pubitemid 19094619)
24. De Serres J, Groner A, and Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: A review. Transfus Apheresis Sci 29:247-254, 2003. (Pubitemid 37321355)
25. Altman AD, McLaughlin J, Schellenberg R, et al. Hereditary angioedema managed with low-dose danazol and c1 esterase inhibitor concentrate: A case report. J Obstet Gynaecol Can 28:27-31, 2006.
26. Lehmann A, Lang J, Boldt J, and Saggau W. Successful off-pump coronary artery bypass graft surgery in a patient with hereditary angioedema. J Cardiothorac Vasc Anesth 16:473-476, 2002. (Pubitemid 34839708)
27. Leimgruber A, Jaques WA, and Spaeth PJ. Hereditary angioedema: Uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy. Int Arch Allergy Immunol 101:107-112, 1993. (Pubitemid 23179084)
28. Maves KK, and Weiler JM. Tonsillectomy in a patient with hereditary angioedema after prophylaxis with C1 inhibitor concentrate. Ann Allergy 73:435-438, 1994. (Pubitemid 24368199)
29. Mohr M, Pollok-Kopp B, Gotze O, and Burchardi H. The use of a C1-inhibior concentrate for short-term preoperative prophylaxis in two patients with hereditary angioedema. Anaesthesist 45:626-630, 1996. (Pubitemid 26241360)
30. Szema AM, Paz G, Merriam L, et al. Modern preoperative and intraoperative management of hereditary angioedema. Allergy Asthma Proc 30:338-342, 2009.
31. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513-522, 2010.
32. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126:821-827, 2010.
33. Juhlin L, and Michaelsson G. Use of a kallikrein inhibitor in the treatment of urticaria and hereditary angioneurotic edema. Acta Derm Venereol 49:37-44, 1969.
34. Bauer J, Futterman S, and Dreiling DA. Anaphylactic shock secondary to initial Trasylol administration. Am J Gastroenterol 56:542-544, 1971.
35. Proud G, and Chamberlain J. Letter: Anaphylactic reaction to aprotinin. Lancet 2:48-49, 1976.
36. Williams A, and Baird LG. DX-88 and HAE: A developmental perspective. Transfus Apheresis Sci 29:255-258, 2003. (Pubitemid 37315589)
37. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523-531, 2010.
38. Garnock-Jones KP. Ecallantide: In acute hereditary angioedema. Drugs 70:1423-1431, 2010.
39. Riedl M, Campion M, Horn PT, and Pullman WE. Response time for ecallantide treatment of acute hereditary angioedema attacks. Ann Allergy Asthma Immunol 105:430-436, 2010.
40. Zuraw BL. Efficacy of ecallantide for the acute treatment of hereditary angioedema (HAE) attacks involving the head and neck. Am J Rhinol Allergy 25:369, 2011.
41. Sheffer AL, Campion M, Levy RJ, et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: Integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol 128:153-159, 2011.
42. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: In vitro studies. Br J Pharmacol 102:769-773, 1991.
43. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532-541, 2010.
44. Shire reports positive efficacy and safety results from FAST-3 study of FIRAZYR® (icatibant) for acute attacks of hereditary angioedema 2010. Available online at http://www.shire.com/shireplc/en/investors/irshirenews?id= 431; last accessed October 2011.
45. Riedl M. Clinical outcomes with icatibant in the open-label treatment of 45 laryngeal attacks of hereditary angioedema. Western Society of Allergy Asthma and Immunology, Maui, Hawaii, 2011.
46. Levi M, Choi G, Picavet C, and Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 117:904-908, 2006.
47. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 6:22, 2010. (PMCID: 2922091.)
48. Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, et al. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 49:1987-1995, 2009.
49. Cicardi M, Bork K, Caballero T, et al. Guidelines for treatment of angioedema due to hereditary c1 inhibitor deficiency. Report from the Consensus Meeting of the Hereditary Angioedema International Working Group, Gargnano del Garda, Italy, 2010.